List of Excipients in Branded Drug LITHIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Precision Dose Inc	LITHIUM	lithium	68094-757	ANHYDROUS CITRIC ACID
Precision Dose Inc	LITHIUM	lithium	68094-757	RASPBERRY
Precision Dose Inc	LITHIUM	lithium	68094-757	SODIUM BENZOATE
Precision Dose Inc	LITHIUM	lithium	68094-757	SORBITOL
Precision Dose Inc	LITHIUM	lithium	68094-757	WATER
Hikma Pharmaceuticals USA Inc.	LITHIUM CARBONATE	lithium carbonate	0054-8528	CALCIUM STEARATE

Generic Drugs Containing LITHIUM

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	GLYCERIN
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	HYDROCHLORIC ACID
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	METHYLPARABEN
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	PROPYLENE GLYCOL
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	PROPYLPARABEN

What are the Most Frequently-Used Excipients in LITHIUM?

# Of NDCs	Excipient
3	ALCOHOL
2	ANHYDROUS CITRIC ACID
3	CITRIC ACID MONOHYDRATE
2	GLYCERIN
1	HYDROCHLORIC ACID
1	METHYLPARABEN

Excipient Strategy and Commercial Opportunities for Lithium as a Pharmaceutical Drug

Last updated: March 7, 2026

What Are the Core Excipient Strategies for Lithium Formulations?

Lithium, used mainly in psychiatric medications such as lithium carbonate and lithium citrate, requires excipient strategies focused on stability, bioavailability, and patient safety. The primary considerations include:

• Disintegrants and Fillers: Lithium formulations often incorporate excipients like microcrystalline cellulose and starch to optimize tablet disintegration and stability.

• Binders: Hydroxypropyl methylcellulose (HPMC) and povidone are used to maintain tablet integrity during manufacturing and storage.

• Lubricants: Magnesium stearate prevents sticking and ensures smooth manufacturing processes.

• Coatings: Film coats made from hydroxypropyl cellulose or PEG protect lithium from environmental degradation and mask unpleasant taste, enhancing patient compliance.

• Solubilizers: For formulations such as lithium citrate, the use of polyols like sorbitol enhances solubility.

The choice and combination of excipients aim to maximize bioavailability, minimize gastrointestinal irritation, and stabilize lithium in various controlled-release formulations.

What Are the Key Commercial Opportunities in Lithium Pharmaceutical Development?

The global lithium market for pharmaceuticals is expanding due to rising mental health concerns, particularly bipolar disorder, depression, and treatment-resistant conditions. Market segments include immediate-release and controlled-release formulations, with opportunities in novel delivery systems.

Market Size and Growth

• Estimated global market value exceeds USD 1 billion, with a compound annual growth rate (CAGR) of approximately 5% projected until 2028 (reported by Fortune Business Insights[1]).

• Increasing demand in North America and Europe driven by psychiatric care needs; Asia-Pacific shows rapid growth due to expanding healthcare infrastructure.

Opportunities for Innovation

• Extended-release formulations: Improve compliance and reduce toxicity risks by maintaining stable plasma lithium levels. Patents for extended-release lithium products, such as Lithobid, have expiration dates around 2028-2030, opening avenues for generic development.

• Liquid formulations: Lithium citrate solutions for rapid absorption, used in acute scenarios, with potential for reformulation into pre-measured, low-sodium solutions to enhance patient convenience.

• Novel delivery systems: Transdermal patches and implantable devices are under exploration for steady lithium delivery, reducing side effects and dosing frequency.

• Combination therapies: Integrating lithium with other mood stabilizers or antipsychotics, enabled by compatible excipient formulations, may address multiple symptoms simultaneously.

Regulatory and Patent Landscape

• Lithium drugs face patent expirations, allowing generic manufacturers to enter markets with cost-competitive products.

• Regulatory authorities emphasize safety and efficacy, reinforcing the need for excipient optimization to meet quality standards.

What Are the Challenges and Risks in Excipient and Formulation Development?

• Lithium's narrow therapeutic index demands precise control of drug release and plasma levels, complicating excipient selection.

• Some excipients may induce gastrointestinal irritation or interact with lithium, impacting absorption and tolerability.

• Developing novel or controlled-release formulations increases regulatory hurdles due to demonstrating consistent release profiles and bioequivalence.

What Are the Strategic Implications for Industry Stakeholders?

• Innovation in excipient technology can differentiate products; for instance, utilizing advanced polymers for sustained release.

• Manufacturing efficiencies can be improved through scalable excipient blends compatible with existing processing methods.

• Investing in alternative delivery systems potentially captures unmet needs, such as improved patient adherence and reduced side effects.

• Patent expirations create opportunities for generics and biosimilars, provided formulations meet regulatory standards.

Key Takeaways

• Excipient strategies focus on stabilization, controlled release, and patient tolerability for lithium formulations.

• The pharmaceutical market for lithium is growing, driven by mental health treatment needs, with significant opportunities in sustained-release and novel delivery systems.

• Patent expirations from leading products open corridors for generic and biosimilar entrants.

• Formulation development must address lithium's narrow therapeutic index and associated safety concerns.

FAQs

Q1: How do excipients influence lithium bioavailability?
A: Excipients like fillers and solubilizers enhance dissolution and absorption, affecting plasma concentrations and therapeutic efficacy.

Q2: What are the main safety considerations in lithium formulation?
A: Excipients must not irritate gastrointestinal mucosa, interfere with lithium absorption, or contribute to toxicity.

Q3: Are there approved transdermal lithium delivery systems?
A: Current commercial formulations do not include transdermal systems; research remains ongoing for such delivery routes.

Q4: How does patent expiration impact market competition?
A: Expired patents for key formulations enable generics, increasing market competition and reducing prices.

Q5: What role do novel excipient materials play in future lithium drugs?
A: They enable controlled-release formulations, improved stability, and patient adherence, expanding treatment options.

---

References

[1] Fortune Business Insights. (2022). Lithium Market Size, Share & Industry Trends. Market Research Reports.